The short version of lipolysis fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-29. Anything still debated is marked as such rather than presented as settled.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
By contrast, K-selected species display traits associated with living at densities close to carrying capacity, and typically are strong competitors in such crowded niches that invest more heavily in fewer offspring, each of which has a relatively high probability of surviving to adulthood (i.e., low r, high K). Between these two extremes, the American kestrel is one of the few raptor species that lean towards being r-selected. They are able to breed at one year old, have few non-breeding adults in the population, and have larger broods. Their population growth rate is high relative to larger raptors, which typically lean towards being K-selected. This said, older American kestrel pairs generally have larger brood sizes and produce more viable offspring than younger conspecifics.
In 1988, Bio-Synthesis helped in the synthesis and characterization of a new class of peptides with novel antimicrobial properties discovered at the NIH. In 1989, OCS became incorporated as Bio-synthesis, Inc. and moved its laboratories to Lewisville, Texas. In 1993, Bio-Synthesis was one of the first peptide synthesis companies to acquire a Finnigan MALDI-TOF mass spectrometer for the accurate quality control of synthetic peptides produced in-house. In 1994, Bio-synthesis pioneered the use of molecular methods for HLA analysis which is applied in organ matching for transplantation purposes. Later in the same year Bio-Synthesis held the first major HLA DNA typing workshop with the attendance of HLA laboratory directors from around the country in conjunction with University of North Texas in Denton Texas.
Iron-sulfur protein NUBPL (IND1) also known as nucleotide-binding protein-like (NUBPL), IND1 homolog, Nucleotide-binding protein-like or huInd1 is an iron-sulfur (Fe/S) protein that, in humans, is encoded by the NUBPL gene, located on chromosome 14q12. It has an early role in the assembly of the mitochondrial complex I assembly pathway. NUBPL is located on the q arm of chromosome 14 in position 12 and has 18 exons. The NUBPL gene produces a 5.9 kDa protein composed of 54 amino acids. The structure of the protein includes a presumed iron-sulfur binding (CxxC) signature, a nucleotide-binding domain which has been highly conserved, and a mitochondrial targeting sequence in the N-terminal. NUBPL is required for the assembly of complex I, which is composed of 45 evolutionally conserved core subunits, including both mitochondrial DNA and nuclear encoded subunits. One of its arms is embedded in the inner membrane of the mitochondria, and the other is embedded in the organelle. The two arms are arranged in an L-shaped configuration. The total molecular weight of the complex is 1MDa.
This domain is also found in ghrelin, a growth hormone secretagogue synthesised by endocrine cells in the stomach. Ghrelin stimulates growth hormone secretagogue receptors in the pituitary. These receptors are distinct from the growth hormone-releasing hormone receptors, and, thus, provide a means of controlling pituitary growth hormone release by the gastrointestinal system. Erythromycin has an advantage over metoclopramide in gastric emptying due to lack of central nervous system side-effects. It is not approved by FDA to use for gastric emptying. For short duration for patients with diabetes and for those that must clear the stomach for any procedure, it may be used based on the physician's discretion with full understanding that it is not approved by FDA for this use. GHRL; Motilin; Motilin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Nosek TM. "Section 6/6ch2/s6ch2_26". Essentials of Human Physiology. Archived from the original on 2016-03-24.
TTP's (ZFP36's) expression is rapidly induced by insulin. Immunoprecipitation experiments have shown that TTP co-precipitates with an exosome, suggesting that it helps recruit exosomes to the mRNA containing AREs. TTP appears to promote the processive deadenylation activity of CCR4–NOT on mRNAs containing AREs, with phosphorylation-dependent interactions with cytoplasmic poly(A)-binding protein (PABPC1) potentially enhancing deadenylation and promoting regulated mRNA decay. TTP can also repress mRNA translation after binding to AREs by using 4EHP-GYF2 as a cofactor. Alternatively, HuR proteins have a stabilizing effect—their binding to AREs increases the half-life of mRNAs. Similar to other RNA-binding proteins, this class of proteins contain three RRMs, two of which are specific to ARE elements. A likely mechanism for HuR action relies on the idea that these proteins compete with other proteins that normally have a destabilizing effect on mRNAs. HuRs are involved in genotoxic response—they accumulate in the cytoplasm in response to UV exposure and stabilize mRNAs that encode proteins involved in DNA repair.
Sources: en.wikipedia.org
Lutetium is a chemical element; it has symbol Lu and atomic number 71. It is a silvery white metal which resists corrosion in dry air, but not in moist air. Lutetium is the last element in the lanthanide series, and it is traditionally counted among the rare earth elements; it can also be classified as the first element of the sixth-period transition metals. Lutetium was independently discovered in 1907 by French scientist Georges Urbain, Austrian mineralogist Baron Carl Auer von Welsbach, and American chemist Charles James. All of these researchers found lutetium as an impurity in ytterbium. The dispute on the priority of the discovery occurred shortly after, with Urbain and Welsbach accusing each other of publishing results influenced by the published research of the other; the naming honor went to Urbain, as he had published his results earlier. He chose the name lutecium for the new element honoring the Latin name for Paris, Lutetia. In 1949 the spelling was changed to lutetium. In 1909, the priority was finally granted to Urbain and his names were adopted as official ones; however, the name cassiopeium (or later cassiopium) for element 71 proposed by Welsbach was used by many German scientists until the 1950s. Lutetium is not a particularly abundant element, although it is significantly more common than silver in the Earth's crust. It has few specific uses. Lutetium-176 is a relatively abundant (2.6%) radioisotope with a half-life of about 38 billion years, used to determine the age of minerals and meteorites.
29 November Astronomers report the discovery of a star, HD 110067, that contains six sub-Neptune exoplanets with radii ranging from 1.94R⊕ to 2.85R⊕. The first example of a planet-forming disk beyond the Milky Way galaxy is reported by astronomers using the ALMA in Chile. The system, designated as HH 1177, is located in the Large Magellanic Cloud, about 160,000 light years away. 30 November Researchers demonstrate multicellular microbots grown from a human cell, "anthrobots", that can move around in tissues in vitro. A trial comparing a healthy vegan and a healthy omnivorous diet in identical twins finds the former to be substantially better according to cardiometabolic measures like LDL-C after 8 weeks. Promising innovations relating to global challenges are reported: an efficient electrocaloric heat pump for sustainable cooling (16 Nov), taste-tested bioreactor-grown cultured coffee (17 Nov), an autonomous laboratory for synthesis of inorganic powders, the A-Lab (29 Nov), a solar tower design using downdraft technology for hot and dry weather areas that could generate twice the electricity of solar updraft systems and operate at night, the Twin-Technology Solar System (TTSS) (30 Nov). Promising results of health and medical research are reported: phase 2-trialed Mazdutide against type-2 diabetes (9 Nov), phase 1-trialed lepodisiran against cardiovascular risk factor lipoprotein (12 Nov), rat-tested depot technology for sustained delivery of GLP-1 receptor agonists against the need for frequent injections (21 Nov).
=== Pharmaceuticals and cosmetics === Emulsifiers are essential for producing water-in-oil emulsions, e.g. for skin creams. They are also necessary for a wide range of suspensions to maintain liquid drug formulations.
=== Stage === The phrase "On the Bowery", which has since fallen into disuse, was a generic way to say one was down-and-out. It originated in the song "The Bowery" from the 1891 musical A Trip to Chinatown, which includes the chorus "The Bow'ry, The Bow'ry!/They say such things,/and they do strange things/on the Bow'ry, the Bow’ry!/I’ll never go there anymore.”". On the Bowery, an 1894 play starring Steve Brodie, supposed Brooklyn Bridge jumper and Bowery saloonkeeper. In Disney's Newsies, the showgirls featured in the song "I Never Planned on You/Don't Come a-Knocking" are called the Bowery Beauties.
Cereulide 2-methyl-5-HT Alpha-Methyltryptamine Bufotenin Chlorophenylbiguanide Ibogaine Phenylbiguanide Quipazine RS-56812 – Potent and selective 5-HT3 partial agonist, 1000× selectivity over other serotonin receptors SR-57227 Varenicline YM-31636 S 21007 (SAR c.f. CGS-12066A)
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.